Blueprint Medicines Corp (NAS:BPMC)
$ 96.53 -1.09 (-1.12%) Market Cap: 6.13 Bil Enterprise Value: 5.94 Bil PE Ratio: 0 PB Ratio: 19.54 GF Score: 81/100

Blueprint Medicines Corp at Cowen Health Care Conference Transcript

Mar 12, 2019 / 12:40PM GMT
Release Date Price: $83.78 (-0.45%)
Marc Frahm
Cowen and Company - Analyst

Okay. Good morning. Welcome back to the Cowen Health Care Conference. I'm Marc Frahm from the biotech team. Next up we have Blueprint Medicines, a leader in targeted therapies for oncology but also now -- emerging also with some rare disease programs as well that are getting in the clinic.

And I'll turn it over to Jeff Albers, the CEO, to tell us more.

Jeff Albers
Blueprint Medicines Corporation - CEO

Great. Marc and the Cowen team, on behalf of all the employees at Blueprint Medicines, thank you for including us here today. As always, we will be making forward-looking statements and would refer you to our SEC filing documents, and disclaim any obligation to update any of those statements.

Blueprint Medicines has a very clear mission, and that's to craft highly selective and potent kinase medicines for patients with genomically defined diseases. And what you see here on the left-hand side of the screen are two kinome trees. Each branch represents a kinase, and a red dot goes to where this inhibition

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot